Scott Chan

Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.

Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.

Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.

Analyst Articles

The island country of Taiwan has done a fantastic job of containing Covid-19. As recently as early May this year, there were very few new cases each day. However, the success caused complacency in some people and Taiwan finally had a surge in cases. By the end of May, the… Read More

In a landmark move, against the advice of its panel of experts, in June the FDA approved Biogen’s aducanumab (branded Aduhelm), marking the first-ever approval of an Alzheimer’s drug. Despite mixed data from Biogen’s Phase 3 trials, due to the urgent need for something, the FDA gave the nod anyway. Read More

Bad news for Vertex Pharmaceuticals (NSDQ: VRTX). The company announced that it will give up further development of VX-864, a drug candidate being evaluated as treatment for alpha-1 antitrypsin deficiency (AATD). AATD is a rare genetic disorder that causes patients to produce insufficient amounts of the protein AAT, which in… Read More

We are begrudgingly selling JD.com (NSDQ: JD) and Tencent (OTCMKTS: TCEHY). This was a tough decision. On the one hand, Chinese stocks offer direct exposure to the Chinese consumer market, the size and growth of which are unmatched by any other country. But on the other hand, Chinese stocks do… Read More